Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
Thomas D. Madden
Advertisement
Thomas D. Madden, PhD, is CEO of Acuitas Therapeutics.
Articles by Thomas D. Madden
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
2
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
3
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
4
Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule
5